Business Wire

Pfizer Announces Oral Tofacitinib, an Investigational JAK Inhibitor, Meets Primary and Key ...

NEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE:PFE) announced today the oral presentation of detailed results from the first two pivotal Phase 3 studies from the Oral Clinical Trials for tofAcitinib in ...